"We found CKD to be independently associated with a higher likelihood of nonorgan confined disease and lymph node metastases as well as postoperative transfusion and 90-day readmissions." – Nguyen, et ...
"The main strength of this study is the use of a nationwide population-based cohort encompassing nearly all patients with bladder cancer undergoing RC over 8 years, with detailed clinicopathological, ...
This transcript has been edited for clarity. Cheryl Lee, MD: Welcome to Medscape InDiscussion. I'm Cheryl Lee, and today we'll be discussing a topic that has continued to be controversial. I'm ...
RARC with intracorporeal urinary diversion offers survival outcomes similar to those of open radical cystectomy, but is associated with better perioperative outcomes. Real-world data support the ...
PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of ...
Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...
Partial cystectomy for muscle-invasive bladder cancer offers metastasis- and cancer-free survival comparable to that of radical cystectomy, but with less perioperative morbidity. Partial and radical ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...
New data show that a large subset of patients with muscle-invasive bladder cancer (MIBC) can avoid cystectomy and enjoy long-term, bladder-intact, disease-free survival. Among 64 study participants ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...
Use of robot-assisted vs. open radical cystectomy led to a significantly increased number of days alive and out of the hospital among patients with nonmetastatic bladder cancer. Perspective from David ...